Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

RA was well tolerated in the Phase I trial. Now MBX is planning a Phase II trial in post-bariatric hypoglycaemia patients.

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...

The study showed diabetic patients taking GLP-1 drugs, such as semaglutide and tirzepatide, faced significantly lower risks of 30-day readmission, wound re-opening and hematoma after surgery, compared ...

For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

This is the beginning of a revolution, and how you engage and how you attack it is going to really set the stage for your ...

The U.S. Food and Drug Administration has approved the first generic version of Victoza (liraglutide injection), ...

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

For this review, the authors searched for randomized controlled trials published in MEDLINE, Embase, and Cochrane CENTRAL ...

The following is a summary of “Association of Perioperative Glucagon-like Peptide-1 Receptor Agonist Use and Postoperative ...

Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...